Roivant Sciences (NASDAQ:ROIV) Shares Gap Up – Should You Buy?

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) gapped up prior to trading on Wednesday. The stock had previously closed at $34.92, but opened at $38.15. Roivant Sciences shares last traded at $37.2320, with a volume of 3,777,833 shares changing hands.

Key Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Brepocitinib met both Phase 3 primary endpoints. Roivant and Priovant reported that the CLARITY-1 and CLARITY-2 trials achieved their primary goals in non-infectious uveitis. The drug also delivered statistically significant and clinically meaningful improvements in key secondary measures, including sustained steroid-free disease control, reduced vascular leakage, resolution of macular edema and better patient-reported visual functioning. Roivant and Priovant announce positive brepocitinib Phase 3 results
• Positive Sentiment: The trial data could expand the drug’s commercial opportunity. Coverage highlighted brepocitinib’s ability to reduce reliance on steroids in inflammatory eye disease, while Roivant is expected to pursue a label expansion for Lisraya in uveitis. Positive commentary and analyst coverage contributed to the stock’s upward move. Roivant’s TYK2/JAK inhibitor reduces need for steroids
• Neutral Sentiment: Roivant will report fiscal second-quarter results on November 9, 2026. Investors will receive updated financial results and a business outlook, including any regulatory or commercialization plans related to brepocitinib. Roivant quarterly earnings announcement
• Negative Sentiment: CEO Eric Venker sold 200,000 shares worth approximately $7.0 million. The sale reduced his direct ownership by 12.5%, which may draw investor attention. However, it was executed under a pre-arranged Rule 10b5-1 trading plan, reducing its significance as a discretionary bearish signal. SEC insider transaction filing

Analyst Ratings Changes

Several equities research analysts recently issued reports on ROIV shares. Jefferies Financial Group raised their target price on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Guggenheim boosted their price target on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. UBS Group set a $55.00 price objective on Roivant Sciences in a research note on Wednesday, September 9th. Finally, Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.64.

Roivant Sciences Stock Up 1.8%

The stock has a market capitalization of $27.05 billion, a price-to-earnings ratio of -70.66 and a beta of 1.10. The company’s fifty day simple moving average is $36.61 and its 200 day simple moving average is $33.32.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. As a group, analysts anticipate that Roivant Sciences Ltd. will post -2.00 earnings per share for the current year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $36.10, for a total transaction of $640,775.00. Following the completion of the sale, the director directly owned 14,954 shares in the company, valued at $539,839.40. This trade represents a 54.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 284,707 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75. Following the sale, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $675,364,288.75. This represents a 1.51% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 1,822,688 shares of company stock worth $65,848,636. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

Large investors have recently made changes to their positions in the company. Alpine Bank Wealth Management bought a new stake in Roivant Sciences in the 3rd quarter valued at $25,000. Parallel Advisors LLC increased its position in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after buying an additional 520 shares during the period. Bessemer Group Inc. increased its position in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after buying an additional 441 shares during the period. Root Financial Partners LLC increased its position in Roivant Sciences by 187.9% during the 1st quarter. Root Financial Partners LLC now owns 2,914 shares of the company’s stock worth $81,000 after buying an additional 1,902 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Roivant Sciences by 76.1% during the first quarter. EverSource Wealth Advisors LLC now owns 4,433 shares of the company’s stock worth $123,000 after buying an additional 1,916 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.